← Eichor
Condition: Grade Iv Glioma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Grade Iv Glioma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
Phase 1/Phase 2 · 3 location(s) · Institute of Cancer Research, United Kingdom · NCT06630260ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV G
Phase 1 · 2 location(s) · Jonsson Comprehensive Cancer Center · NCT07089641A Phase 2 Study of HX301 in Patients with High-grade Giloma
Phase 1/Phase 2 · 1 location(s) · Hangzhou Hanx Biopharmaceuticals, Ltd. · NCT06703255The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients.
NA · 5 location(s) · Jasper Gerritsen · NCT03861299Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
Phase 1 · 1 location(s) · Plus Therapeutics · NCT05460507Implantable Microdevice In Primary Brain Tumors
EARLY_Phase 1 · 1 location(s) · Oliver Jonas · NCT04135807Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT07468136Dabrafenib and/or Trametinib Rollover Study
Phase 4 · 32 location(s) · Novartis Pharmaceuticals · NCT03340506Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme
EARLY_Phase 1 · 1 location(s) · Stony Brook University · NCT05423210Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
Phase 1 · 4 location(s) · Tcelltech Inc. · NCT06482905Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progress
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06815029BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors
EARLY_Phase 1 · 1 location(s) · Nader Sanai · NCT07485049Study of Olutasidenib and Temozolomide in HGG
Phase 2 · 20 location(s) · Rigel Pharmaceuticals · NCT06161974Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
Phase 2 · 27 location(s) · National Cancer Institute (NCI) · NCT05859334Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4)
NA · 2 location(s) · Medical University of Warsaw · NCT07488754Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astr
Phase 1 · 43 location(s) · National Cancer Institute (NCI) · NCT06860594Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT06964737Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
Phase 2 · 3 location(s) · Academic and Community Cancer Research United · NCT06160206Safety and Effectiveness Evaluation of Temozolomide (Amitzo, NanoAlvand) in Patients With Grade III and IV Glioma Tumors
Phase N/A · 1 location(s) · NanoAlvand · NCT07675070A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
Phase 2 · 1 location(s) · Case Comprehensive Cancer Center · NCT07003542Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
Phase 1 · 1 location(s) · Northwestern University · NCT06410248Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Phase 1 · 11 location(s) · Memorial Sloan Kettering Cancer Center · NCT06934889SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Phase 3 · 57 location(s) · Nuvation Bio Inc. · NCT05303519Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression
Phase 1 · 1 location(s) · Case Comprehensive Cancer Center · NCT05565118Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT04991870Targeted Pediatric High-Grade Glioma Therapy
Phase N/A · 21 location(s) · Nationwide Children's Hospital · NCT05839379GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma an
Phase 2 · 1 location(s) · Mayo Clinic · NCT07301268A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Pat
EARLY_Phase 1 · 1 location(s) · Nader Sanai · NCT07268053Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas
Phase 2 · 1 location(s) · Marzieh Ebrahimi · NCT06687681Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Phase 1/Phase 2 · 3 location(s) · Plus Therapeutics · NCT01906385
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.